SEC filing · 8-K

Scynexis Inc: Material agreement

SCYNEXIS secured a contract with BARDA providing up to $214 million in potential funding to develop its antifungal candidate SCY-247.

Filed September 28, 2026

Positive for the company

What happened

On September 25, 2026, SCYNEXIS entered into a contract with the Biomedical Advanced Research and Development Authority (BARDA).

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Scynexis Inc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.